Do analysts rate BMGL or BIAF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, BMGL or BIAF?

Basel Medical Group has higher revenue and earnings than bioAffinity Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 0.84 -$9.50M N/A N/A bioAffinity Technologies $5.85M 1.55 -$14.91M -$109.45 N/A

Does the media prefer BMGL or BIAF?

In the previous week, bioAffinity Technologies had 7 more articles in the media than Basel Medical Group. MarketBeat recorded 8 mentions for bioAffinity Technologies and 1 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 1.14 beat bioAffinity Technologies' score of -0.32 indicating that Basel Medical Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Basel Medical Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive bioAffinity Technologies 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate MGRX or BIAF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer BIAF or AIDX?

20/20 Biolabs has a consensus price target of $5.00, suggesting a potential upside of 745.31%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than bioAffinity Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend GXAI or BIAF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend NIVF or BIAF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, NIVF or BIAF?

NewGenIvf Group has higher earnings, but lower revenue than bioAffinity Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.48 $9.88M N/A N/A bioAffinity Technologies $5.85M 1.55 -$14.91M -$109.45 N/A

Does the media prefer NIVF or BIAF?

In the previous week, bioAffinity Technologies had 1 more articles in the media than NewGenIvf Group. MarketBeat recorded 8 mentions for bioAffinity Technologies and 7 mentions for NewGenIvf Group. NewGenIvf Group's average media sentiment score of 1.51 beat bioAffinity Technologies' score of -0.32 indicating that NewGenIvf Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewGenIvf Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive bioAffinity Technologies 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

bioAffinity Technologies (BIAF) Competitors

$15.27 +2.49 (+19.48%)

As of 09/4/2026 04:00 PM Eastern

Compare

BIAF vs. BMGL, MGRX, AIDX, GXAI, and NIVF

Should you buy bioAffinity Technologies stock or one of its competitors? bioAffinity Technologies's main competitors and comparable companies include Basel Medical Group (BMGL), Mangoceuticals (MGRX), 20/20 Biolabs (AIDX), Gaxos.ai (GXAI), and NewGenIvf Group (NIVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does bioAffinity Technologies compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Basel Medical Group has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.11, meaning that its stock price is 211% less volatile than the broader market.

In the previous week, bioAffinity Technologies had 7 more articles in the media than Basel Medical Group. MarketBeat recorded 8 mentions for bioAffinity Technologies and 1 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 1.14 beat bioAffinity Technologies' score of -0.32 indicating that Basel Medical Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Basel Medical Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
bioAffinity Technologies	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

1.6% of bioAffinity Technologies shares are held by institutional investors. 2.7% of bioAffinity Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Basel Medical Group has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. Basel Medical Group's return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
bioAffinity Technologies	-257.30%	-220.52%	-136.76%

Basel Medical Group has higher revenue and earnings than bioAffinity Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	0.84	-$9.50M	N/A	N/A
bioAffinity Technologies	$5.85M	1.55	-$14.91M	-$109.45	N/A

Summary

Basel Medical Group beats bioAffinity Technologies on 7 of the 11 factors compared between the two stocks.

How does bioAffinity Technologies compare to Mangoceuticals?

Mangoceuticals (NASDAQ:MGRX) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Mangoceuticals has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.11, meaning that its share price is 211% less volatile than the broader market.

In the previous week, bioAffinity Technologies had 8 more articles in the media than Mangoceuticals. MarketBeat recorded 8 mentions for bioAffinity Technologies and 0 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.32 indicating that Mangoceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Mangoceuticals	Neutral
bioAffinity Technologies	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by company insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

bioAffinity Technologies has a net margin of -257.30% compared to Mangoceuticals' net margin of -4,794.60%. Mangoceuticals' return on equity of -96.39% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
bioAffinity Technologies	-257.30%	-220.52%	-136.76%

bioAffinity Technologies has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	19.27	-$20.64M	-$1.01	N/A
bioAffinity Technologies	$5.85M	1.55	-$14.91M	-$109.45	N/A

Summary

Mangoceuticals beats bioAffinity Technologies on 8 of the 13 factors compared between the two stocks.

How does bioAffinity Technologies compare to 20/20 Biolabs?

bioAffinity Technologies (NASDAQ:BIAF) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

20/20 Biolabs has a consensus price target of $5.00, suggesting a potential upside of 745.31%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than bioAffinity Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, bioAffinity Technologies had 8 more articles in the media than 20/20 Biolabs. MarketBeat recorded 8 mentions for bioAffinity Technologies and 0 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.32 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company	Overall Sentiment
bioAffinity Technologies	Neutral
20/20 Biolabs	Neutral

1.6% of bioAffinity Technologies shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 29.8% of 20/20 Biolabs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

20/20 Biolabs has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. 20/20 Biolabs' return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-257.30%	-220.52%	-136.76%
20/20 Biolabs	N/A	N/A	N/A

20/20 Biolabs has lower revenue, but higher earnings than bioAffinity Technologies. 20/20 Biolabs is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$5.85M	1.55	-$14.91M	-$109.45	N/A
20/20 Biolabs	$2.04M	3.70	-$3.74M	-$0.54	N/A

Summary

20/20 Biolabs beats bioAffinity Technologies on 11 of the 15 factors compared between the two stocks.

How does bioAffinity Technologies compare to Gaxos.ai?

Gaxos.ai (NASDAQ:GXAI) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Gaxos.ai has a net margin of -64.81% compared to bioAffinity Technologies' net margin of -257.30%. Gaxos.ai's return on equity of -38.79% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gaxos.ai	-64.81%	-38.79%	-36.99%
bioAffinity Technologies	-257.30%	-220.52%	-136.76%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

42.6% of Gaxos.ai shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, bioAffinity Technologies had 8 more articles in the media than Gaxos.ai. MarketBeat recorded 8 mentions for bioAffinity Technologies and 0 mentions for Gaxos.ai. Gaxos.ai's average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.32 indicating that Gaxos.ai is being referred to more favorably in the media.

Company	Overall Sentiment
Gaxos.ai	Neutral
bioAffinity Technologies	Neutral

Gaxos.ai has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.11, suggesting that its stock price is 211% less volatile than the broader market.

Gaxos.ai has higher earnings, but lower revenue than bioAffinity Technologies. Gaxos.ai is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gaxos.ai	$1.93M	2.79	-$3.90M	-$0.50	N/A
bioAffinity Technologies	$5.85M	1.55	-$14.91M	-$109.45	N/A

Summary

Gaxos.ai beats bioAffinity Technologies on 10 of the 13 factors compared between the two stocks.

How does bioAffinity Technologies compare to NewGenIvf Group?

NewGenIvf Group (NASDAQ:NIVF) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

66.2% of NewGenIvf Group shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, bioAffinity Technologies had 1 more articles in the media than NewGenIvf Group. MarketBeat recorded 8 mentions for bioAffinity Technologies and 7 mentions for NewGenIvf Group. NewGenIvf Group's average media sentiment score of 1.51 beat bioAffinity Technologies' score of -0.32 indicating that NewGenIvf Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewGenIvf Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
bioAffinity Technologies	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NewGenIvf Group has higher earnings, but lower revenue than bioAffinity Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.48	$9.88M	N/A	N/A
bioAffinity Technologies	$5.85M	1.55	-$14.91M	-$109.45	N/A

NewGenIvf Group has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.11, suggesting that its stock price is 211% less volatile than the broader market.

NewGenIvf Group has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. NewGenIvf Group's return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
bioAffinity Technologies	-257.30%	-220.52%	-136.76%

Summary

NewGenIvf Group beats bioAffinity Technologies on 8 of the 11 factors compared between the two stocks.

Get bioAffinity Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIAF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIAF vs. The Competition

Export

Metric	bioAffinity Technologies	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.57M	$10.10B	$7.28B	$12.92B
Dividend Yield	N/A	2.59%	2.54%	8.90%
P/E Ratio	-0.14	34.60	272.43	25.42
Price / Sales	1.55	4.91	629.13	94.56
Price / Cash	N/A	121.75	77.39	52.28
Price / Book	2.40	3.99	12.85	6.17
Net Income	-$14.91M	$313.25M	$3.47B	$349.50M
7 Day Performance	213.55%	1.06%	0.97%	-0.15%
1 Month Performance	92.15%	0.33%	5.47%	1.02%
1 Year Performance	-85.80%	15.31%	24.29%	14.50%

bioAffinity Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIAF bioAffinity Technologies	0.6101 of 5 stars	$15.27 +19.5%	N/A	-85.8%	$7.57M	$5.85M	N/A	10	News Coverage Gap Down High Trading Volume
BMGL Basel Medical Group	0.962 of 5 stars	$5.08 -8.6%	N/A	-79.4%	$8.70M	$8.90M	N/A	36	Positive News
MGRX Mangoceuticals	0.4716 of 5 stars	$0.39 +0.2%	N/A	-81.5%	$8.41M	$460K	N/A	3	Gap Down
AIDX 20/20 Biolabs	2.0779 of 5 stars	$0.62 -0.1%	$5.00 +712.2%	N/A	$7.87M	$2.05M	N/A	14	Gap Up
GXAI Gaxos.ai	0.31 of 5 stars	$0.80 -3.8%	N/A	-51.6%	$5.91M	$1.93M	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIAF) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

bioAffinity Technologies (BIAF) Competitors

BIAF vs. BMGL, MGRX, AIDX, GXAI, and NIVF

How does bioAffinity Technologies compare to Basel Medical Group?

Summary

How does bioAffinity Technologies compare to Mangoceuticals?

Summary

How does bioAffinity Technologies compare to 20/20 Biolabs?

Summary

How does bioAffinity Technologies compare to Gaxos.ai?

Summary

How does bioAffinity Technologies compare to NewGenIvf Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF vs. The Competition

bioAffinity Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

bioAffinity Technologies (BIAF) Competitors

BIAF vs. BMGL, MGRX, AIDX, GXAI, and NIVF

How does bioAffinity Technologies compare to Basel Medical Group?

Do analysts rate BMGL or BIAF?

Which has more risk & volatility, BMGL or BIAF?

Does the media prefer BMGL or BIAF?

Do institutionals and insiders believe in BMGL or BIAF?

Is BMGL or BIAF more profitable?

Which has better valuation and earnings, BMGL or BIAF?

Summary

How does bioAffinity Technologies compare to Mangoceuticals?

Which has more volatility and risk, MGRX or BIAF?

Does the media prefer MGRX or BIAF?

Do analysts rate MGRX or BIAF?

Do insiders & institutionals believe in MGRX or BIAF?

Is MGRX or BIAF more profitable?

Which has preferable valuation & earnings, MGRX or BIAF?

Summary

How does bioAffinity Technologies compare to 20/20 Biolabs?

Do analysts prefer BIAF or AIDX?

Does the media favor BIAF or AIDX?

Do insiders and institutionals hold more shares of BIAF or AIDX?

Is BIAF or AIDX more profitable?

Which has higher valuation and earnings, BIAF or AIDX?

Summary

How does bioAffinity Technologies compare to Gaxos.ai?

Is GXAI or BIAF more profitable?

Do analysts recommend GXAI or BIAF?

Do institutionals & insiders hold more shares of GXAI or BIAF?

Does the media refer more to GXAI or BIAF?

Which has more risk and volatility, GXAI or BIAF?

Which has stronger valuation and earnings, GXAI or BIAF?

Summary

How does bioAffinity Technologies compare to NewGenIvf Group?

Do institutionals and insiders hold more shares of NIVF or BIAF?

Does the media prefer NIVF or BIAF?

Do analysts recommend NIVF or BIAF?

Which has better earnings & valuation, NIVF or BIAF?

Which has more volatility and risk, NIVF or BIAF?

Is NIVF or BIAF more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF vs. The Competition

bioAffinity Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools